As part of a multi-year RWE initiative, AMCP Research Institute partnered with IQVIA, payers, pharmaceutical companies, and others to design payer-focused RWE standards that were published in JMCP in September, 2025.
Best Practice Handout - Health Plan Best Practice – Chronic Lymphocytic Leukemia (CLL)
Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disorder (lymphoid neoplasm). It is characterized by a progressive accumulation of functionally incompetent B lymphocytes, which are usually monoclonal in origin. View the fact sheet on JMCP that includes:
- Current Recommended Treatments in CLL
- What Oncology Specialists Recommend Various First-Line CLL Treatments
- Suggested Treatment Algorithm in Patients Intolerant of 1st Generation BTK Inhibitor
- Important Factors to Consider when Calculating the Total Cost of Care for CLL
- Suggested CLL/SLL Treatment Pathways
For more disease state research, view the Market Insights Program.
Related
AMCP’s guidance translates CMS’s expectations for patient centered, evidence informed formulary decisions into practical steps payers can act on today without adding unnecessary burden to P&T workflows.
Metabolic diseases drive rising costs and disparities, yet evidence‑based care remains inconsistent. AMCP is advancing guidance, education, and collaboration to support aligned coverage, equitable access, and improved outcomes.
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
